BDX Shares Rise 5.9% Following Q2 Revenue Beat, Raised EPS Guidance

BDX posted a strong fiscal Q2 2026 with revenue of $4.71 billion — 5.2% higher year-over-year — exceeding analyst consensus of $4.67 billion . Adjusted EPS came in at $2.90, beating the $2.78 estimate through operational leverage across the company's Medical and Life Sciences segments. The earnings beat drove a 5.9% single-session share gain, one of Becton Dickinson's stronger post-earnings reactions in recent trading history.

Management responded to the strong quarter by raising full-year adjusted EPS guidance to $12.52-$12.72 per share, implying 5.2-6.9% growth over fiscal 2025's $11.90 — a guidance raise analysts viewed as potentially conservative given the Q2 beat trajectory . The company noted approximately 120 basis points of favorable currency impact on revenue, suggesting that underlying constant-currency performance was equally solid. Adjusted operating margins came in near 25%, reflecting continued progress under the company's BD Excellence cost discipline program.

BDX's results carry broader read-through implications for the healthcare equipment sector, where companies with consistent earnings beats and guidance raises typically command premium multiples. The company's diversified product mix — spanning diagnostics, medication management systems, and laboratory automation — provides insulation against single-segment pricing pressure from GPO negotiations or CMS reimbursement changes. With the guidance raise in hand, analysts are revisiting price targets, and the stock's post-earnings gain positions Becton Dickinson as a standout performer in the healthcare equipment sub-sector year-to-date.

Related Stocks

• BDX